CBD Manufacturer Recalls Injectable Products After FDA Warning
By
Posted on
Another CBD company has issued a voluntary product recall
Another CBD company has issued a voluntary product recall after the U.S. Food and Drug Administration flagged it for making unsubstantiated claims.
Biota Biosciences, a Seattle-based CBD manufacturer, is recalling lots from three injectable products sold by distributors to consumers that were being marketed without FDA approval:
- Cannabidiol (CBD) Complex, marketed to suppress pain and aid detoxification as a promising therapeutic for medical disorders such as epilepsy.
- Curcurmin Complex, marketed as an anti-inflammatory and antioxidant that could help with symptoms of depression and arthritis.
- Cannabidiol + Curcurmin, marketed as a more-efficient therapeutic effect.
Prior to the recall, the FDA had notified Biota Biosciences that the marketing material on its website that made unapproved product claims made its products unapproved new drugs sold in violation of the federal Food, Drug and Cosmetic Act.
To Read The Rest Of This Article On Hemp Industry Daily, Click Here
